Fig. 3.

MTX-LNC treatment increases the expression and activity of CD73 in the cells of the glioblastoma microenvironment. Rats with implanted glioblastoma were treated with 1.0 mg/kg/day MTX-LNCs for 10 days. After tumor isolation, immunohistochemistry was carried out using a Nikon Eclipse e800 microscope (×400) to visualize CD73 expression in the control (a) and MTX-LNC-treated group (b). Additionally, CD73 expression was determined by immunostaining followed by flow cytometry (c). AMP hydrolysis in the cells of the GBM microenvironment was measured using the malachite green method (d). The values represent the mean ± SEM from at least four animals. Asterisk indicates a significant difference from the LNC vehicle group (p < 0.05) as determined by one-way ANOVA followed by Tukey’s test